Motavizumab for the prevention of respiratory syncytial virus infection in infants

Michelle A. Gill, Robert C. Welliver

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Respiratory syncytial virus (RSV) is the most important respiratory viral pathogen of infancy. The only unequivocally effective pharmacological compound for the management of RSV infection is palivizumab, a monoclonal antibody against the fusion protein of RSV. Recently, motavizumab, a similar but more potent monoclonal antibody, has been developed and tested against palivizumab. Objective: In this review, we summarize data comparing the safety and efficacy of the two monoclonal antibodies in prevention of RSV infection. Other therapeutic options also are discussed. Methods: We reviewed all published articles listing motavizumab or palivizumab in the title or keywords. Results/conclusion: In a large comparative clinical trial for which peer review is pending, motavizumab proved noninferior to palivizumab for prevention of RSV-related hospital admission in infants with underlying conditions placing them at high risk for hospitalization after RSV infection. In this trial, motavizumab in comparison to palivizumab significantly reduced the severity of illness among those infants hospitalized with RSV infection, as well as the number of outpatient lower respiratory infections caused by RSV. Safety profiles of each of the two compounds were excellent. Based on these data, motavizumab should eventually replace palivizumab in the prevention of RSV infection.

Original languageEnglish (US)
Pages (from-to)1335-1345
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume9
Issue number10
DOIs
StatePublished - Oct 2009

Fingerprint

Respiratory Syncytial Virus Infections
Viruses
Respiratory Syncytial Viruses
Monoclonal Antibodies
Safety
Peer Review
Respiratory Tract Infections
motavizumab
Palivizumab
Hospitalization
Outpatients
Clinical Trials
Pathogens
Pharmacology
Fusion reactions
Proteins

Keywords

  • Bronchiolitis
  • Monoclonal antibody
  • Motavizumab
  • Palivizumab
  • Respiratory syncytial virus

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Motavizumab for the prevention of respiratory syncytial virus infection in infants. / Gill, Michelle A.; Welliver, Robert C.

In: Expert Opinion on Biological Therapy, Vol. 9, No. 10, 10.2009, p. 1335-1345.

Research output: Contribution to journalArticle

@article{ddebc791299146809969f60a2947a148,
title = "Motavizumab for the prevention of respiratory syncytial virus infection in infants",
abstract = "Background: Respiratory syncytial virus (RSV) is the most important respiratory viral pathogen of infancy. The only unequivocally effective pharmacological compound for the management of RSV infection is palivizumab, a monoclonal antibody against the fusion protein of RSV. Recently, motavizumab, a similar but more potent monoclonal antibody, has been developed and tested against palivizumab. Objective: In this review, we summarize data comparing the safety and efficacy of the two monoclonal antibodies in prevention of RSV infection. Other therapeutic options also are discussed. Methods: We reviewed all published articles listing motavizumab or palivizumab in the title or keywords. Results/conclusion: In a large comparative clinical trial for which peer review is pending, motavizumab proved noninferior to palivizumab for prevention of RSV-related hospital admission in infants with underlying conditions placing them at high risk for hospitalization after RSV infection. In this trial, motavizumab in comparison to palivizumab significantly reduced the severity of illness among those infants hospitalized with RSV infection, as well as the number of outpatient lower respiratory infections caused by RSV. Safety profiles of each of the two compounds were excellent. Based on these data, motavizumab should eventually replace palivizumab in the prevention of RSV infection.",
keywords = "Bronchiolitis, Monoclonal antibody, Motavizumab, Palivizumab, Respiratory syncytial virus",
author = "Gill, {Michelle A.} and Welliver, {Robert C.}",
year = "2009",
month = "10",
doi = "10.1517/14712590903287499",
language = "English (US)",
volume = "9",
pages = "1335--1345",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Motavizumab for the prevention of respiratory syncytial virus infection in infants

AU - Gill, Michelle A.

AU - Welliver, Robert C.

PY - 2009/10

Y1 - 2009/10

N2 - Background: Respiratory syncytial virus (RSV) is the most important respiratory viral pathogen of infancy. The only unequivocally effective pharmacological compound for the management of RSV infection is palivizumab, a monoclonal antibody against the fusion protein of RSV. Recently, motavizumab, a similar but more potent monoclonal antibody, has been developed and tested against palivizumab. Objective: In this review, we summarize data comparing the safety and efficacy of the two monoclonal antibodies in prevention of RSV infection. Other therapeutic options also are discussed. Methods: We reviewed all published articles listing motavizumab or palivizumab in the title or keywords. Results/conclusion: In a large comparative clinical trial for which peer review is pending, motavizumab proved noninferior to palivizumab for prevention of RSV-related hospital admission in infants with underlying conditions placing them at high risk for hospitalization after RSV infection. In this trial, motavizumab in comparison to palivizumab significantly reduced the severity of illness among those infants hospitalized with RSV infection, as well as the number of outpatient lower respiratory infections caused by RSV. Safety profiles of each of the two compounds were excellent. Based on these data, motavizumab should eventually replace palivizumab in the prevention of RSV infection.

AB - Background: Respiratory syncytial virus (RSV) is the most important respiratory viral pathogen of infancy. The only unequivocally effective pharmacological compound for the management of RSV infection is palivizumab, a monoclonal antibody against the fusion protein of RSV. Recently, motavizumab, a similar but more potent monoclonal antibody, has been developed and tested against palivizumab. Objective: In this review, we summarize data comparing the safety and efficacy of the two monoclonal antibodies in prevention of RSV infection. Other therapeutic options also are discussed. Methods: We reviewed all published articles listing motavizumab or palivizumab in the title or keywords. Results/conclusion: In a large comparative clinical trial for which peer review is pending, motavizumab proved noninferior to palivizumab for prevention of RSV-related hospital admission in infants with underlying conditions placing them at high risk for hospitalization after RSV infection. In this trial, motavizumab in comparison to palivizumab significantly reduced the severity of illness among those infants hospitalized with RSV infection, as well as the number of outpatient lower respiratory infections caused by RSV. Safety profiles of each of the two compounds were excellent. Based on these data, motavizumab should eventually replace palivizumab in the prevention of RSV infection.

KW - Bronchiolitis

KW - Monoclonal antibody

KW - Motavizumab

KW - Palivizumab

KW - Respiratory syncytial virus

UR - http://www.scopus.com/inward/record.url?scp=70349376986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349376986&partnerID=8YFLogxK

U2 - 10.1517/14712590903287499

DO - 10.1517/14712590903287499

M3 - Article

C2 - 19764889

AN - SCOPUS:70349376986

VL - 9

SP - 1335

EP - 1345

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 10

ER -